Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1998| December  | Volume 19 | Issue 4  
    Online since May 30, 2009

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Distribution of ABO and Rhesus blood groups in gujarat, India : a hospital based study
MK Wadhwa, SM Patel, DC Kothari, M Pandey, DD Patel
December 1998, 19(4):137-141
Blood group distribution shows a wide geographical variation. It is important for running and planning blood banking services, in a setup, to know the distribution pattern in the place where these services are located and the population it caters to. We carried out a retrospective analysis of voluntary blood donations over the last six months at the Gujarat Cancer and Research Institute (GCRI) to understand the blood group distribution patterns prevailing in Gujarat. During the period from November 1995 to May 1996, a total of 5278 volunteers donated blood. Blood group B was found to be the commonest (35.5 percent) followed by O (32.5 percent), A (23.3 percent) and AV (8.8 percent), 5.8 percent of the total donors were Rhesus negative. A significant difference was observed in blood group distribution compared to earlier series from Gujarat and Southern Indian states, while difference was statistically not significant when compared with other Northern states.
[ABSTRACT]   Full text not available   
  1,891 0 -
Morbidity and mortality from infections in Indian Children with acute leukanias
N Lalitha, L Appaji, BS Arunakumari, IT Magrath
December 1998, 19(4):114-120
In this article we describe our experience in treating acute Lymphoblastic leukemia in southern India, paying special attention to the infectious complications encountered. Our of a total of 341 patients less than 25 years of age registered with ALL during the year 1987-92, 206 patients were treated according to a standard treatment protocol (MCP 841 from the National Cancer Institute, USA) Forty percent of the patients were from rural areas and only one third had normal nutritional status (although more than 90 percent had undergone primary Immunization). Forty percent of patients had leukocyte count greater than 50,000 per cumm and 40 percent presented with 'Lymphoma syndrome'. as designated by the CCSG. The documented infections encountered were mainly caused by gram negative bacteria, the most frequent being klebsiella and Psedomonas. Chicken pox and herpes zoster were commonly encountered, and oropharyngeal candiasis frequently complicated chemotherapy. A significant decline in mortality occured over the 4 year period of this protocol based study, due, no doubt, to improved supportive care and routine testing of donated blood for hepatitis B. Deaths prior to therapy, induction deaths and deaths in remission were equally diminished. Induction deaths and deaths in remission were each 4.1 percent in 1990, compared to 9.7 percent and 29 percent respectively in 1987. Familiarization with the infectious complications encountered with intensive treatment protocols, and their management, is vital to the achievement of improved survival results in ALL. inspite of differences in both the patient population and available resources compared to industrialized nations, infectious complications can be kept to an acceptably low level, even with intensive chemotherapy protocols, in the setting of a major cancer institute in a developing country.
[ABSTRACT]   Full text not available   
  715 0 -
Role of paclitaxel as a single agent and in combination with iforfamide in advanced head and neck cancer
VR Pai, K Devendra, AT Mazumdar, DM Parikh, RC Mistry, AR Faikh
December 1998, 19(4):121-128
PURPOSE: To evaluate the efficacy of paclitaxel as a single agent and in combination with ifosfamide in advanced or recurrent head and neck cancer patients. PATIENTS AND METHODS: Thirty one male patients with squamous cell carcinoma were entered in this study. Seven patients received paclitaxel (200 mg/m2), as a single agent and twenty four patients received a fixed dose of ifosfamide (1.5 gm/m2) and one of three escalating dose levels of paclitaxel. In group 1-100 mg/m2, in group 11-140 mg/m2, in group 111-175 mg/m2 paclitaxel was given. Premedication was given prior to paclitaxel (dexamethasone, phenargan, ranitidine). The cycles were repeated at an interval of 4 weeks for a total of three cycles. RESULTS: Six evaluable patients received paclitaxel (200 gm/m2) as a single agent. Ifosfamide and escalating doses of paclitaxel. In group 1(100 mg/m2) five patients, in group II (140 mg/m2) seven patients and group III (175 mg/m2) twelve patients were treated. Whereas no response was observed in group I and only one partial response in group II, four complete and four partial responses were observed in group III. There was no dose limiting hematological and neurotoxicity observed. One patient died two days after the first cycle due to cardiac failure and respiratory distress. CONCLUSION: Paclitaxel shows consistent antitumour effect advanced and recurrent head and neck cancer patients as a single agent and in combination with Ifosfamide.
[ABSTRACT]   Full text not available   
  602 0 -
Multiple myeloma; an unusual presentation : a case report and review of literature
S Shawgi, A Rao, K Nadkarni
December 1998, 19(4):134-136
A unique case of multiple myeloma with an unusual presentation is described here. His presenting complaint was in no way related to his primary diseases. He first presented to the dermatologist with history of multiple small nodules on the anterior abdominal wall. The biopsy of the lesion was reported as lymphoplasmacytic lymphoma. Further investigations revealed that the patient had only multiple myeloma with unusual skin lesions and not lymphoma as reported earlier.
[ABSTRACT]   Full text not available   
  574 0 -
Tomudex in advanced colonic cancer : a case report and literature review
MM Chandiwal, SV Almol, DV Sahani, Ac Kapadia
December 1998, 19(4):129-133
Tomudex (ZD 1694) is a new antifolate which is a specific inhibitor of thymidylate synthase (TS). It has been found to be active in colonic malignancy, either as primary of secondary line therapy. We have used tomudex as a second line treatment in a case of advanced primary colonic carcinoma and partial response was observed. The cytotoxic activity of tomudex is dependent upon uptake into cells via the reduced folate carrier and subsequent metabolism to polyglutamate forms which are approximately sixty fold more active as TS inhibitors. Rational design of the folate TS inhibitor was based on extensive understanding of relationship between chemical structure and biological properties and of analog interactions with TS transport proteins and folypolyglutamase synthase. The development of these folate based TS inhibitor exemplifies a targeted approach to design of new cancer chemotherapeutic agents.
[ABSTRACT]   Full text not available   
  485 0 -
Avascular necrosis of bone in children with all
DC Muralidharan, AS Anand, PM Shah, KM Patel, SN Suhkla, BJ Parekh, SS Talati, SA Shah, B Parekh, RR Shah, K Sajnani, NC Shah, BU Trivedi, M Suthar, UB Parekh
December 1998, 19(4):142-147
Treatment advances have resulted in increased survival of children with Acute Lymphoblastic Leukemia (ALL). Increasing success in the treatment of ALL has lead to the increasing awareness of potentially disabling sequelae of the therapy, like Avascular Necrosis of Bone (AVNB). We present 4 cases, who developed AVNB as a sequel to treatment of ALL, and the relevant litreture is discussed.
[ABSTRACT]   Full text not available   
  467 0 -
Arsenic trioxide in the treatment of acute promyelocytic leukemia
N Geetha
December 1998, 19(4):111-113
Full text not available   
  279 0 -